These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 31714287)

  • 1. Potassium binding for conservative and preservative management of chronic kidney disease.
    Clegg DJ; Palmer BF
    Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):29-38. PubMed ID: 31714287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
    Palmer BF
    Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
    Santoro A; Mandreoli M
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
    Tamargo J; Caballero R; Delpón E
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hyperkalemia - current therapuetic strategies].
    Głogowski T; Wojtaszek E
    Wiad Lek; 2016; 69(5):745-748. PubMed ID: 28033600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in treatment of hyperkalemia in chronic kidney disease.
    Sarafidis PA; Georgianos PI; Bakris GL
    Expert Opin Pharmacother; 2015; 16(14):2205-15. PubMed ID: 26330193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
    Takkar C; Nassar T; Qunibi W
    Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New potassium binders effective: treatment of hyperkalaemia secondary to RAAS inhibitors].
    Hoorn EJ
    Ned Tijdschr Geneeskd; 2015; 159():A8801. PubMed ID: 25761299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drugs to prevent and treat hyperkalemia.
    Lepage L; Desforges K; Lafrance JP
    Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):524-528. PubMed ID: 27584929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel potassium binders to optimize RAASi therapy in heart failure: A systematic review and meta-analysis.
    Paolillo S; Basile C; Dell'Aversana S; Esposito I; Chirico A; Colella A; Esposito G; Santo MD; Fierro MF; Carbone F; Marzano F; Amato C; Gargiulo P; Perrone Filardi P
    Eur J Intern Med; 2024 Jan; 119():109-117. PubMed ID: 37648583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.
    Rastogi A; Hanna RM; Mkrttchyan A; Khalid M; Yaqoob S; Shaffer K; Dhawan P; Nobakht N; Kamgar M; Goshtaseb R; Sarmosyan K; Gnarini M; Wassef O; Lerma E
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1055-1064. PubMed ID: 34227913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia.
    Pitt B; Garza D
    Expert Opin Drug Saf; 2018 May; 17(5):525-535. PubMed ID: 29667438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapies for hyperkalemia.
    Leon SJ; Harasemiw O; Tangri N
    Curr Opin Nephrol Hypertens; 2019 May; 28(3):238-244. PubMed ID: 30865167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics.
    Weir MR; Mayo MR; Garza D; Arthur SA; Berman L; Bushinsky D; Wilson DJ; Epstein M
    J Hypertens; 2017 May; 35 Suppl 1(Suppl 1):S57-S63. PubMed ID: 28129247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Management of Hyperkalemia.
    Palmer BF; Carrero JJ; Clegg DJ; Colbert GB; Emmett M; Fishbane S; Hain DJ; Lerma E; Onuigbo M; Rastogi A; Roger SD; Spinowitz BS; Weir MR
    Mayo Clin Proc; 2021 Mar; 96(3):744-762. PubMed ID: 33160639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperkalemia treatment in chronic kidney disease patients: overview on new K binders and possible therapeutic approaches].
    De Stefano T; Borrelli S; Garofalo C; Provenzano M; De Nicola L; Minutolo R; Conte G
    G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer.
    Epstein M; Pitt B
    Expert Opin Pharmacother; 2016 Jul; 17(10):1435-48. PubMed ID: 27180623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updates on medical management of hyperkalemia.
    Lopes MB; Rocha PN; Pecoits-Filho R
    Curr Opin Nephrol Hypertens; 2019 Sep; 28(5):417-423. PubMed ID: 31268919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
    Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
    Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.